Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2014
This article has no abstract
Epistemonikos ID: cd72fbc32efb122035625e9ea4a34e57c7e4088e
First added on: Feb 05, 2025